Open AccessConversion rate of tuberculosis screening tests among dermatology patients treated with tumor necrosis factor inhibitors
Author(s) -
SarahF Alsukait,
AlaaB Alsaad,
GhadahF Alotaibi,
FahadM Alsaif,
HendM Alotaibi
Publication year - 2022
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_201_21
Subject(s) - medicine , tuberculosis , adalimumab , incidence (geometry) , psoriasis , prospective cohort study , retrospective cohort study , tumor necrosis factor α , dermatology , surgery , tumor necrosis factor alpha , pathology , physics , optics
The use of tumor necrosis factor-α inhibitors (TNFi) has been associated with an increased risk latent tuberculosis (TB) reactivation. The role of TB screening assays in monitoring patients during TNFi therapy remains uncertain. Spontaneous conversions and reversions have been described.